|
(Health-NewsWire.Net, April 23, 2021 ) Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours.
Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type
Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=19552
Report Price: $ 4500 (Single User License)
Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application
Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.
Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography
Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.
Inquiry Before Buying @ https://www.industryarc.com/reports/request-quote?id=19552
Clinical Oncology Next Generation Sequencing Market Drivers
Increasing Prevalence of Cancer:
Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.
Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:
In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.
Clinical Oncology Next Generation Sequencing Market Challenges
Major Regulatory Concerns & Lack Skilled Professionals:
Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.
Clinical Oncology Next Generation Sequencing Industry Outlook:
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.
Acquisitions/Product Launches:
In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation
In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.
In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.
Key Takeaways
The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.
Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.
The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.
Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.
Related Reports :
A. Oncology Clinical Trials Market
https://www.industryarc.com/Report/19486/oncology-clinical-trials-market.html
B. Next Generation Sequencing Market
https://www.industryarc.com/Research/Next-Generation-Sequencing-Market-Research-504217
For more Lifesciences and Healthcare Market reports, Please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.
IndustryARC
Venkat Reddy
(+1) 970-236-3677
venkat@industryarc.com
Source: EmailWire.Com 
|
